Pelthos Therapeutics, Inc. (PTHS)
9.48
+0.18
(+1.94%)
USD |
NYAM |
Nov 06, 10:23
Pelthos Therapeutics EPS Diluted (Quarterly) : -6.616 for June 30, 2026
EPS Diluted (Quarterly) Chart
Historical EPS Diluted (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | -6.616 |
| March 31, 2026 | -7.571 |
| December 31, 2025 | -6.868 |
| September 30, 2025 | -5.304 |
| June 30, 2025 | -5.385 |
| March 31, 2025 | -3.211 |
| September 30, 2024 | -0.2926 |
| June 30, 2024 | -0.3068 |
| March 31, 2024 | -0.4443 |
| Date | Value |
|---|---|
| December 31, 2023 | -0.6872 |
| September 30, 2023 | -0.2465 |
| June 30, 2023 | -0.1653 |
| March 31, 2023 | -0.1676 |
| December 31, 2022 | -0.1282 |
| September 30, 2022 | -0.0965 |
| June 30, 2022 | -0.0579 |
| March 31, 2022 | -0.0538 |
EPS Diluted (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
EPS Diluted (Quarterly) Benchmarks
| Travere Therapeutics, Inc. | -0.645 |
| ACADIA Pharmaceuticals, Inc. | 0.305 |
| Alnylam Pharmaceuticals, Inc. | 15.72 |
| Anika Therapeutics, Inc. | 0.2412 |
| Savara, Inc. | -0.1587 |
EPS Diluted (Quarterly) Related Metrics
| Net Income (Quarterly) | -23.42M |
| Revenue (Quarterly) | 15.60M |
| Total Expenses (Quarterly) | 39.02M |
| Enterprise Value | 83.13M |
| Gross Profit Margin (Quarterly) | 68.40% |
| Profit Margin (Quarterly) | -150.1% |
| Earnings Yield | -278.0% |
| Normalized Earnings Yield | -213.10 |